G1 Therapeutics turned research from the University of North Carolina at Chapel Hill into novel cancer drug Cosela, which is approved in the U.S. and China. Pharmacosmos says its G1 acquisition will enable Cosela to reach more lung cancer patients around the world.
Pepper Bio has licensed rights to lerociclib, a molecule that G1 Therapeutics designed to offer dosing and safety advantages over approved therapies in the same drug class. EQRx previously held rights to the drug, but returned them after the company was acquired last year.
Health care professionals can refer patients to the best options for diagnostic imaging covered by Medicare to give more people the medical assistance they need without extra financial stress.
G1 Therapeutics said its drug met the main goal of a Phase 3 study in colorectal cancer, but the preliminary results also show measures of survival are better in the placebo arm. The company is stopping the colorectal cancer study.